logo-loader

Clinigen licenses first drug to Cumberland through alliance

Last updated: 13:05 10 May 2016 BST, First published: 08:05 10 May 2016 BST

cancer-cells
“This exclusive agreement with Ethyol is the first with Cumberland but others will follow"

Clinigen Group PLC (LON:CLIN) has licensed its first drug to US pharma Cumberland Pharmaceuticals under an alliance agreed last year.

The two companies will work together in the US to market Ethyol, an FDA-approved treatment to reduce xerostomia or dry mouth.

Xerostomia is a side-effect in patients undergoing post-operative radiation treatment for head and neck cancer.

Cumulative renal toxicity in ovarian cancer sufferers taking cisplatin can also be reduced by the drug.

Nasdaq-listed Cumberland (NASDAQ:CPIX)   will be responsible for all marketing, promotion, and distribution of the product in the US.

Clinigen acquired the worldwide rights to Ethyol from AstraZeneca in 2014  and Peter George, chief executive, said this was an important step in the revitalization plan for the product.

"Our strategic alliance with Cumberland is a key part of our continuing strategy to develop our global footprint for our Specialty Pharmaceuticals business.

“This exclusive agreement with Ethyol is the first with Cumberland but others will follow.

“This market is key in revitalising our products and we are also keen to make this important brand available to more patients in treating particularly difficult side effects of their cancer treatment." 

AJ Kazimi, Cumberland’s chief executive, said: "We have been very selective in the brands that we bring into our portfolio and believe Ethyol will be an excellent fit for our hospital sales organisation.”

Last week, Clinigen unveiled a reformulation of its best selling drug Foscavir, which treats a range of herpes viruses.

Caledonia Mining tackles 2023 challenges with optimism for 2024 as it...

Caledonia Mining Corporation PLC (AIM:CMCL, NYSE-A:CMCL) chief executive Mark Learmonth tells Proactive's Stephen Gunnion the company faced a challenging 2023, primarily due to poor production in the first half of the year at its core asset, the Blanket Mine in Zimbabwe, and an underperformance...

33 minutes ago